2114-37-6

Basic information

• Product Name: Benzene, 1-(1-bromopropyl)-4-methyl-
• CAS NO: 2114-37-6
• Molecular Formula: C10H13Br
• Molecular Weight: 213.117
• Mol File: 2114-37-6.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Benzene, 1-(1-bromopropyl)-4-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene, 1-(1-bromopropyl)-4-methyl-(2114-37-6)
• EPA Substance Registry System: Benzene, 1-(1-bromopropyl)-4-methyl-(2114-37-6)

Safety Data

• Hazardous Substances Data: 2114-37-6(Hazardous Substances Data)

Upstream product

• 5337-93-9 4'-methylpropiophenone 
• 104-87-0 4-methyl-benzaldehyde 
• 4294-57-9 para-methylphenylmagnesium bromide 
• 25574-04-3 1-p-tolyl-1-propanol 

Downstream Products

• 104316-19-0 2-(4-methyl)-phenyl-butyronitrile 
• 57960-06-2 β-ethyl-4-methylbenzenepropanoic acid 

Relevant articles and documents

Copper-Catalyzed Enantioconvergent Cross-Coupling of Racemic Alkyl Bromides with Azole C(sp2)?H Bonds

The development of enantioconvergent cross-coupling of racemic alkyl halides directly with heteroarene C(sp2)?H bonds has been impeded by the use of a base at elevated temperature that leads to racemization. We herein report a copper(I)/cinchona-alkaloid-derived N,N,P-ligand catalytic system that enables oxidative addition with racemic alkyl bromides under mild conditions. Thus, coupling with azole C(sp2)?H bonds has been achieved in high enantioselectivity, affording a number of potentially useful α-chiral alkylated azoles, such as 1,3,4-oxadiazoles, oxazoles, and benzo[d]oxazoles as well as 1,3,4-triazoles, for drug discovery. Mechanistic experiments indicated facile deprotonation of an azole C(sp2)?H bond and the involvement of alkyl radical species under the reaction conditions.

Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives

The present invention relates a method for treating depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I wherein R, R1, R2, A and n are as defined in the specification and to their pharmaceutically active salts. The invention also relates to novel compounds of formula I, pharmaceutical compositions containing them, and methods for their preparation.